Merck's Keytruda (pembrolizumab) Receives FDA's Approval as a Monotherapy for 1L+ Recurrent Locally Advanced or Metastatic Esophageal Cancer Expressing PD-L1 (CPS ≥10)
Shots:
- The approval is based on two studies- KEYNOTE-181 study results involve assessing of Keytruda (200mg- q3w) vs CT (paclitaxel/docetaxel) in 628 patients in a ratio (1:1) with 1L+ LA/m- EC with disease progression. The KEYNOTE-180 study results involve assessing of Keytruda in 121 patients with 1L+ LA/m- EC with disease progression
- KEYNOTE-181 results: In ESCC patients with PD-L1 expression (CPS ≥10) (80% vs 88%); OS (10.3 vs 6.7mos.); mPFS (3.2 vs 2.3 mos.); ORR (22% vs 7%); CRR (5% vs 1%); DOR (9.3 vs 7.7mos.). KEYNOTE-180 results: 20% ORR with DOR ranged from 4.2-25.1+ mos.
- Keytruda is a mAb targeting PD-1 and blocking its interaction with PD-L1 and PD-L2 thereby activating T-lymphocytes affecting both tumor and healthy cells
Click here to read full press release/ article
Ref: Merck | Image: Merck
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com